Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Analysts Raise Price Targets Following Strong Data From Revolution Medicines' Pancreatic Cancer Drug

Revolution Medicines, Inc. (NASDAQ:RVMD) stock is trading higher after the company shared updates from its Daraxonrasib Phase 1 trials on Wednesday.

Benzinga

UK must heed Sir John Bell’s big pharma investment warning

Instead of making silly statements the government needs to look at why Merck has scrapped its £1bn research centre

The Guardian - UK

Why Is AbbVie Stock Trading Higher On Thursday?

AbbVie Inc. (NYSE:ABBV) stock is trading higher on Thursday following an SEC filing that settled litigation with all generic manufacturers, which filed abbreviated new drug applications with the U.S. Food and Drug Administration for generic versions of upadacitinib tablets, marketed by the company as Rinvoq.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pharma giant ditches £1bn London research hub and says UK ‘is not internationally competitive’

Merck, known as MSD in Europe, criticised the UK’s business environment despite the government saying it has become ‘the most attractive place to invest in the world’

The Independent UK

Big pharma will stop investing in UK, top scientist warns after Merck’s £1bn exit

Comments by former professor of medicine at Oxford follow scrapping of planned London research centre

The Guardian - UK

Merck scraps £1bn London expansion as report warns UK drugs sector ‘losing out’

UK pharmaceutical sector ‘risks losing investment to other countries’.

Evening Standard

BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) on Wednesday released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, which demonstrated that BXCL501 had continued effects and consistent benefit with repeat dosing.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Synopsys Shares Are Trading Lower Wednesday: What's Going On?

Synopsys, Inc. (NASDAQ:SNPS) shares are trading lower Wednesday after the company reported worse-than-expected financial results and issued fourth quarter adjusted earnings per share guidance below estimates on Tuesday after the market closed. Also, the company cut its fiscal-year 2025 adjusted earnings per share guidance below estimates.

Benzinga

US drugmaker Merck scraps £1bn London research centre and cuts 125 science jobs

New blow to UK’s key life science sector as industry body says country is losing ground on investment and research

The Guardian - UK

Gov. Greg Abbott orders minors banned from THC products

Lt. Gov. Dan Patrick on Friday called Abbott’s decision a pathway to full legalization of cannabis, including marijuana which is still federally illegal. Hemp-derived THC is legal.

The Texas Tribune

Hims & Hers Bets On Hormonal Health To Revive Investor Confidence

Hims Hers Health Inc. (NYSE:HIMS) launched a new category in men’s health on Wednesday, offering access to affordable and personalized treatment plans for low testosterone.

Benzinga

Weight loss drugmaker to slash 9,000 jobs in £926 million cost cut

Novo Nordisk was at one point last year Europe's most valuable listed company

The Independent UK

Novo Nordisk To Cut 9,000 Jobs As Competition From Eli Lilly Heats Up: Analyst Calls Move 'Tough, Natural...Very Necessary'

Novo Nordisk (NYSE:NVO) has announced a significant restructuring plan that will see the company cut 9,000 jobs, representing 11.5% of its workforce. The decision comes as the pharmaceutical giant faces mounting pressure from U.S. competitor Eli Lilly (NYSE:LLY).

Benzinga

Top 3 Health Care Stocks You'll Regret Missing In Q3

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments.

Benzinga

Rapport Therapeutics, Planet Labs, QuantumScape, EchoStar And Other Big Stocks Moving Higher On Monday

U.S. stocks were mixed, with the Nasdaq Composite gaining over 150 points on Monday.

Benzinga

Top 4 Biotech Stocks Set For A Breakout: Momentum Scores Surge

Several biotech stocks are showing renewed strength over the past week, with their Momentum scores soaring in Benzinga’s Edge Stock Rankings.

Benzinga

Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing

Billionaire entrepreneur Mark Cuban, in a series of posts on the social media platform X early Monday morning, launched a scathing critique of the U.S. prescription drug industry, accusing large wholesalers and Pharmacy Benefit Managers (PBMs) of creating a “stranglehold” on pricing through opaque, anti-competitive practices.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga

Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth

Investors are increasingly looking to biotechnology companies for potential breakthroughs and profitable returns, as the sector shows resilience and growth amid broader market volatility. Within this landscape, Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is capturing attention with its promising drug portfolio and financial performance.

Benzinga

Why Is Sanofi Stock Falling Thursday?

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga

TG Therapeutics CEO Voices Strong Conviction In Briumvi With New $100 Million Buyback

TG Therapeutics Inc. (NASDAQ:TGTX) shares advanced Wednesday after the biopharmaceutical company announced the completion of a $100 million share repurchase program and unveiled plans for an additional $100 million buyback authorization.

Benzinga

4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week

Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga’s Edge Stock Rankings witnessing a significant decline.

AAP

'Super lab': man denied bail after huge meth haul

A man has been accused of trying to flee overseas when police allegedly uncovered a drug "super lab" they claim could have produced $500 million worth of meth.

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.